Capstone Investment Advisors
MLYS icon

Capstone Investment Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Capstone Investment Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Sell
8,374
-1,301
-13% -$35.7K ﹤0.01% 1569
2026
Q1 		$262K Buy
+9,675
New +$284K ﹤0.01% 1414
2025
Q4 		– Sell
-42,276
Closed -$1.6M – 1891
2025
Q3 		$1.6M Buy
+42,276
New +$914K ﹤0.01% 851

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capstone Investment Advisors's MLYS Position: Q2 2026 in Review

Capstone Investment Advisors reduced its Mineralys Therapeutics (MLYS) stake by 13% in Q2 2026, selling an estimated $35.7K and leaving 8,374 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #1569.

Capstone Investment Advisors first reported a position in MLYS in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.6M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Capstone Investment Advisors held 8,374 shares of Mineralys Therapeutics worth $226K as of Q2 2026.
  • Capstone Investment Advisors sold 1,301 Mineralys Therapeutics shares in Q2 2026, an estimated $35.7K.
  • Mineralys Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1569 holding.
  • Capstone Investment Advisors first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Capstone Investment Advisors's Mineralys Therapeutics position peaked at $1.6M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.